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Summary Introduction: Despite their unfavourable
cardiovascular risk profile, patients with glycogen
storage disease type Ia (GSD Ia) do not develop
premature atherosclerosis. We hypothesized that this
paradox might be related to a decreased formation of
advanced glycation end products (AGEs) resulting
from lifetime low plasma glucose levels and decreased
oxidative stress. Methods: In 8 GSD Ia patients (age
20–34 years) and 30 matched controls we measured
carotid intima-media thickness (IMT), skin autofluor-
escence (AF; a non-invasive index for AGEs), and
specific AGEs (pentosidine, N-(carboxymethyl)lysine
(CML), N-(carboxyethyl)lysine (CEL)) and collagen
linked fluorescence (CLF, measured at excitation/
emission wavelength combinations of 328/378 and
370/440 nm) in skin samples. Results: Carotid IMT
was significantly lower in GSD Ia patients. Skin AF
did not differ between patients and controls. The skin
samples showed higher CEL levels in the patient group
(p=0.008), but similar levels of pentosidine, CML, and
CLF. In the total group, skin AF correlated with CML
(r=0.39, p=0.031), CLF 328/378 nm (r=0.53; p=0.002)
and CLF 370/440 nm (r=0.60; p=0.001). In the control
group, AF also correlated with the maximum carotid
IMT (r=0.6; p=0.004). Conclusion: Although our data
confirm that GSD Ia patients present with a reduced
burden of atherosclerosis, this phenomenon cannot be
explained by differences in AGE accumulation as
measured in the skin.
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Introduction
Glycogen storage disease type Ia (GSD Ia, von Gierke
disease; OMIM +232200) is an inborn error of metab-
olism, caused by deficiency of microsomal glucose-6-
phosphatase (G6Pase; EC 3.1.3.9) in liver and kidney.
G6Pase is a key enzyme in homeostatic regulation of
blood glucose concentration by catalysing the terminal
step in both glycogenolysis and gluconeogenesis.
Although the main feature of this disease is severe
fasting hypoglycaemia, several other metabolic
changes complicate the disease. GSD Ia patients have
marked hyperlipidaemia, characterized by a high total
cholesterol with a low level of high-density lipoprotein
(HDL) and, most strikingly, high triglyceride levels, a
result of both increased synthesis and, possibly,
decreased plasma lipid clearance. Another long-term
complication is renal failure. After a silent period of
hyperfiltration, patients develop microalbuminuria and
eventually frank proteinuria during the first three
decades of life. Dyslipidaemia and microalbuminuria
are known to be strong risk factors for atherosclerosis
and cardiac disease (Verhave et al 2005; Yudkin et al
1988). As patients are surviving longer, the concern
has risen that GSD Ia patients may be at high risk for
atherosclerosis as well (Levy et al 1988). However, in
contrast to other diseases associated with exposure to
cardiovascular risk factors at an early age, such as
familial hypercholesterolaemia (Wiegman et al 2004),
it has been shown that GSD Ia patients do not show
any signs of endothelial dysfunction or premature
atherosclerosis (Lee 1994; Talente et al 1994; Ubels
et al 2002).
Recently, the accumulation of advanced glycation
end products (AGEs) on tissue proteins has been
implicated as a contributing factor in atherosclerosis
(Forbes et al 2004; Kiuchi et al 2001; Nakamura et al
1993; Ritthaler et al 1995). AGEs are a heterogeneous
group of compounds formed by the Maillard reaction,
or the non-enzymatic browning reaction that modifies
proteins with carbohydrate-and lipid-derived inter-
mediates (Thorpe and Baynes 2003). AGE formation
is increased in hyperglycaemia and under the influence
of oxidative stress (Elgawish et al 1996; Thorpe and
Baynes 2003; Wells-Knecht et al 1995, 1997; Wolff and
Dean 1987). AGE formation alters the characteristics
of both short- and long-lived (e.g. collagen) proteins.
AGEs accumulate in extracellular matrix proteins but
also in atherosclerotic plaques (Nakamura et al 1993;
Schleicher et al 1997) and the expression of receptors
for AGEs (RAGE) is increased in atherosclerosis
(Ritthaler et al 1995). Interaction of AGE-modified
proteins with AGE receptors may stimulate cytokine
and growth factor production that sustains the devel-
opment of the atherosclerotic plaques.
We therefore postulated that as increased AGE
formation leads to atherosclerosis, decreased AGE
formation might protect against this disease. We
hypothesized that GSD Ia patients have lower AGE
levels based on two observations. First, GSD Ia
patients may be more frequently hypoglycaemic
(Hershkovitz et al 2001; Rake et al 2002). Second
and most importantly, GSD Ia patients have signifi-
cantly lower levels of oxidative stress (Wittenstein et al
2002). The finding of low AGE levels in women with
polycystic ovary syndrome, a common complication in
GSD Ia (Rake et al 2002) that also increases the risk
for atherosclerosis, also contributes to this hypothesis
(Diamanti-Kandarakis et al 2005).
In the current study, we assessed AGEs in tissue
both by quantification of specific AGEs and measure-
ment of collagen linked fluorescence (CLF) in skin
biopsies, and by measuring skin autofluorescence
(AF), using a recently developed and validated meth-
od (Mulder et al 2006). We aimed to investigate
whether patients with GSD Ia present with lower
levels of AGE accumulation compared with age- and
sex-matched healthy controls.
Methods
Subjects
A total of 38 adults were enrolled in this study, 8 GSD
patients (2 male and 6 female) of age 18–36 (27T7)
years and 30 healthy control subjects matched for age
and sex (8 male and 22 female). All GSD patients aged
Q18 years, who attended our outpatient clinic or were
admitted during the study period, were approached for
participation and age-matched controls were
approached after the selection of individual patients.
All participants were assessed with the procedures
described below during the same study period. Rele-
vant information on medical history and smoking
habits was obtained from both patients and control
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Ethical Committee and written informed consent was
obtained from all participants.
Skin autofluorescence (AF)
Skin AF was assessed on the ventral site of the lower
arm with a prototype of the current AGE-Reader
(DiagnOptics BV, Groningen, The Netherlands) as
described elsewhere (Meerwaldt et al 2004, 2005b;
Mulder et al 2006). In short, the AGE-Reader consists
of a tabletop box containing a black light excitation
light source (peak wavelength õ360 nm). Light emit-
ted from the skin is measured with an integrated
spectrometer. Measurement is fully automated and
takes approximately 30 s to perform, giving an average
value over 50 individual scans. Skin AF is calculated
by dividing the mean value of the emitted light
intensity per nm between 420 and 600 nm by the mean
value of the excitation light intensity per nm between
300 420 nm, expressed as arbitrary units (AU). The
intra-individual Altman error percentage is 5.0% on a
single day and 5.9% for seasonal changes (Meerwaldt
et al 2004).
Carotid intima-media thickness (IMT) measurement
IMT of the carotid arteries was measured by ultraso-
nography in the supine position. High-resolution
B-mode ultrasound imaging (ACUSON 128 XP;
Acuson Corp, Mountain View, CA, USA) with a
7.0 MHz linear array transducer was used to measure
intima-media wall thickness, as described previously in
greater detail (Terpstra et al 2004). In short, the right
and left common carotid arterial wall segments were
imaged from a fixed lateral transducer angle at the far
wall of the distal 1 cm segments of both common
carotid arteries (CCA), proximal to the carotid bulb.
The far wall of the carotid bulb (CB), and of the most
proximal part of the internal carotid artery (ICA) were
also scanned bilaterally. The scans were recorded on
S-VHS tape and analysed offline by an independent
image analyst unaware of subject characteristics.
B-mode image analyses were digitized with a frame
grabber (DT286 l; Data Translation, Marlboro, MA,
USA). The image analysis software was developed
using an algorithm developed by Selzer and colleagues
(Selzer et al 1994) The average and maximum carotid
IMT over the six segments (CCA, CB and ICA,
bilaterally far wall) of both carotid arteries were cal-
culated. At a mean IMT of 0.80 mm, intersonographer
variability amounted to 0.05 mm, with an image
analyst variability <0.03 mm, corresponding to a total
variation coefficient between 6.3% and 7.3%.
Blood and urine collection
Venous blood and a portion of urine were taken non-
fasting to measure glycated haemoglobinA1c (HbA1c),
lipid spectrum, creatinine and urine albumin, using rou-
tine laboratory methods.
Skin samples and measurement of AGEs
A 4 mm diameter full-thickness skin biopsy was taken
under 2% lidocaine–adrenaline anaesthesia from the
volar (frontal) side of the lower arm. The sample was
snap-frozen in liquid nitrogen and stored at j80-C.
After thawing, insoluble collagen was extracted as
previously described (Fu et al 1994; Meerwaldt et al
2004); the samples were reduced with sodium borohy-
dride and solubilized using pepsin. Then collagen
linked fluorescence (CLF) was measured using wave-
lengths of 328/378 nm and 370/440 nm (excitation/
emission). Both CLF and pentosidine were normalized
to the hydroxyproline content of the sample measured
according to Stegemann and Stalder (1967). Pentosi-
dine was measured by high-performance liquid chro-
matography as described by Dyer and colleagues
(1993). N-(Carboxymethyl)lysine (CML) and N-
(carboxyethyl)lysine (CEL) analysis was performed
by gas chromatography-mass spectrometry as de-
scribed by Dunn and colleagues (Ahmed et al 1997).
CML and CEL were normalized to the lysine content
of the sample.
Statistical analysis
Owing to the low prevalence of the disease, we could
not include more than 8 adult patients with GSD Ia for
this study. We determined that with this number of
patients and an expected standard deviation of 0.25, a
sample size of 30 controls would be needed to give the
study 80% power at a=0.05 to detect at least a
difference of 20% between both groups.
Because of the small group measured, data are
given as medians (interquartile range). Mann–Whitney
test was performed to compare groups and Spearman_s
rho test to calculate correlations. All analyses were
performed with SPSS version 13.0 for Windows (SPSS,
Chicago, IL, USA). A value of p<0.05 was considered
statistically significant.
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One control subject was excluded because micro-
albuminuria appeared to be present. The results of
the skin biopsy measurements from two male subjects
were excluded because the amount of material was not
sufficient to provide reliable data, based on hydroxy-
proline. No sex-based differences were found.
All patients used a xanthine-oxidase inhibitor and 7
out of 8 patients also used an angiotensin-converting
enzyme inhibitor. The observed hyperlipidaemia was
not treated in any of the patients. Other characteristics
of both patient and control groups are listed in
Table 1, which shows that the GSD patients enrolled
in this study had similar levels of HbA1c. The patients
were markedly dyslipidaemic with higher triglycerides,
total cholesterol and lower HDL cholesterol compared
to controls. The maximum carotid IMT and the
average carotid IMT in patients were significantly
lower than in the control group.
Skin AGEs measured in skin samples
Table 2 demonstrates that skin samples of patient
versus control subjects showed comparable amounts of
the AGEs pentosidine and CML. CEL levels were
significantly higher in the patient group (see Fig. 1).
No differences were found between patients and
Table 1 Characteristics of patients and controls
Controls (n=29) Patients (n=8) p-Value
Age (years) 25 (21–32) 27 (20–34) NS
Length (m) 1.78 (1.69–1.85) 1.66 (1.61–1.68) 0.019
Sex (male/female) 8/21 2/6 NS
Body mass index (kg/m
2) 23 (21–26) 24 (22–28) NS
Smoking (n)1 2 N S
HbA1c (%) 4.9 (4.6–5.0) 4.8 (4.6–5.3) NS
Triglycerides (mmol/L) 1.19 (0.88–1.63) 4.05 (3.07–7.10) <0.001
Cholesterol (mmol/L) 4.90 (4.15–5.35) 5.88 (5.22–7.72) 0.012
HDL-cholesterol (mmol/L) 1.44 (1.32–1.76) 1.14 (1.00–1.25) 0.008
LDL-cholesterol (mmol/L) 2.53 (2.10–3.04) 3.07 (1.61–1.68) NS
Creatinine (mmol/L) 81 (75–92) 66 (65–73) 0.002
Creatinine clearance (ml/min)
a 125 (112–142) 143 (123–153) NS
Albumin/creatinine ratio 0.8 (0.5–1.2) 1.2 (0.6–6.9) NS
Average carotid IMT (mm) 0.60 (0.58–0.62)
b 0.53 (0.48–0.59) 0.008
Maximum carotid IMT (mm) 0.77 (0.74–0.81)
b 0.68 (0.60–0.74) 0.004
Data are given as median and interquartile range or as absolute numbers. Differences between groups are calculated with the Mann–
Whitney U-test or chi-squared test where appropriate.
IMT, intima media thickness; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, glycated haemoglobin A1c, NS,
not significant.
aCreatinine clearance as calculated by the Cockcroft–Gault formula.
bn=27.
Table 2 Characteristics of patients and controls
Controls (n=29) Patients (n=8) p-Value
Autofluorescence (10
j2 AU) 1.55 (1.30–1.76) 1.67 (1.57–1.76) NS
Pentosidine (mg/g hydroxyproline) 23.8 (18.0–30.6)
a 19.1 (16.7–28.4)
b NS
CML (mmol/mol lysine) 1.01 (0.81–1.47)
a 1.14 (0.78–1.59)
b NS
CEL (mmol/mol lysine) 0.05 (0.05–0.07)
a 0.09 (0.05–0.13)
b 0.008
CLF 328/378 (AU/mg hydroxyproline) 324 (239–388) 318 (286–374)
b NS
CLF 370/440 (AU/mg hydroxyproline) 203 (163–259) 197 (179–324)
b NS
Data are given as median and interquartile range and differences between groups are calculated with the Mann–Whitney U-test.
CML, N-(carboxymethyl)lysine; CEL, N-(carboxyethyl)lysine; CLF, collagen linked fluorescence; AU, arbitrary units; NS, not
significant.
an=27.
bn=7.
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not show any differences between patients and con-
trols (see Fig. 2).
Correlations between indices for AGE accumulation
and IMT
In patients and controls taken together, skin AF
correlated with CLF 370/440 (r=0.62; p<0.001) and also
with CML (r=0.39; p=0.031) and CLF 328/278 (r=0.53;
p=0.002) (Table 3). Skin AF did not correlate with
pentosidine or CEL. All AGEs measured from skin
biopsies correlated significantly with each other, apart
from CEL which did not correlate with pentosidine.
In the control group, skin AF correlated with
maximum carotid IMT (r=0.60; p=0.004, see Fig. 3),
but not with mean carotid IMT (r=0.33; p=0.139).
Also, in patients and controls together there was no
correlation between carotid IMT and skin AF.
Discussion
In the current study we confirm the previous observa-
tion (Ubels et al 2002) that patients with GSD Ia have
a thinner IMT than healthy controls. This supports the
finding that these patients, despite severe hyperlipi-
daemia and microalbuminuria, do not develop prema-
ture atherosclerosis.
Since GSD Ia patients have lower levels of whole-
body oxidative stress (Wittenstein et al 2002)a n da
strong tendency to develop hypoglycaemia (Rake et al
2002), we hypothesized that decreased formation of
AGEs might protect them from developing premature
atherosclerosis. The data from this study do not
support this hypothesis. GSD Ia patients did not have
lower skin levels of AGEs, as measured either non-
invasively using skin AF or ex vivo in skin samples.
Our data confirm the clinical usefulness of skin AF
as a tool for measuring AGE accumulation in the skin,
since skin AF correlated strongly with the important
representative of the AGEs, CML, and with CLF in
skin biopsies. Additionally, skin AF correlated with
maximum carotid IMT in healthy controls, suggesting
it may be non-invasive index to assess cardiovascular
risk in apparently healthy subjects. The measurement
of skin AF with the AGE-reader is a novel procedure
and it may prove to be a useful tool, since the mea-
surement of AGEs in skin samples has several obvious
limitations, including its invasive nature. The AGE-
reader has been validated in diabetic patients, in hae-
modialysis patients and in healthy controls (Meerwaldt
et al 2004, 2005a). In these validation studies, AF
correlated with the AGEs pentosidine, CML and CEL.
Additionally, skin AF was related to clinical progres-
sion of atherosclerotic disease, since it predicted the
incidence of future cardiovascular morbidity and
mortality in both patient groups (Meerwaldt et al
2005a, 2007). In the current study, we confirm that skin
AF correlates with CML and CLF. However it did not
correlate with CEL and pentosidine. A potential
explanation might be a combination of the small
sample size and the narrow and lower range of CEL
and pentosidine in the current young group with a
small age range compared to previous studies.
Skin biopsies are a generally well-accepted standard
for quantifying AGE accumulation in humans.
Through this method, we found that only CEL is
different in GSD Ia patients. Pentosidine, the AGE
that is exclusively derived from carbohydrates, does
Fig. 2 Skin autofluorescence (AF) in patients and controls; p-
value was calculated with the Mann–Whitney U-test. AU
indicates arbitrary units
Fig. 1 The amount of N-(carboxyethyl)lysine (CEL) in skin
samples of the patients and controls; p-value was calculated with
the Mann–Whitney U-test
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and CEL are both carbohydrate- and lipid-derived.
The hyperlipidaemia in GSD Ia patients might there-
fore explain the elevated CEL levels in skin biopsies.
Our data also show a correlation between triglyceride
levels and CEL (data not shown). However, the
normal CML levels cannot be explained by this theory.
AGE-formation is increased in hyperglycaemia and
during oxidative stress. As expected from current
treatment strategies, HbA1c levels in the GSD
patients are normal and comparable to those of the
controls, which makes important differences in glycae-
mic stress less likely.
In diabetes, elevated AGE levels in skin collagen
are strongly associated with long-term macro- and
microvascular complications (Monnier et al 1986).
Normal (or even partially elevated) AGEs in GSD Ia
patients are not of any help to explain the absence of
atherosclerosis. Wittenstein and colleagues compared
plasma antioxidants in paediatric patients with GSD
Ia, diabetes mellitus and hypercholesterolaemia to
clarify the absence of atherosclerosis (Wittenstein
et al 2002). GSD Ia patients in their study had in-
creased antioxidative defence in plasma, as measured
by the total radical-trapping antioxidant parameter.
However, these might have been strongly influenced
by elevated uric acid levels in GSD Ia, which may be
protective against atherosclerosis (Nieto et al 2000). In
our patient group, all patients used the xanthine-
oxidase inhibitor allopurinol to reduce uric acid levels
in order to prevent gout development, which by itself
also may reduce oxidative stress and has been shown
to improve endothelial dysfunction (Butler et al 2000;
Cardillo et al 1997). These factors may have blurred
the results from our study.
We found little difference in AGE levels between
GSD Ia patients and controls. The extent of renal
disease in GSD Ia also has to be taken into account for
understanding this result, since AGE accumulation is
dependent on renal function (Miyata et al 1998). The
contribution of the risk factor microalbuminuria is
attenuated, because almost all patients used an ACE-
inhibitor. In our study, the albumin/creatinine ratio in
patients did not differ from the ratio in the controls.
The GSD Ia patients in this study did have a
significantly lower creatinine, although the creatinine
clearance calculated by the Cockcroft–Gault formula
did not show any differences from controls. Kidney
disease in GSD Ia is known to start with a period of
silent hyperfiltration (Baker et al 1989; Chen et al
1988; Mundy and Lee 2002). During this period of
hyperfiltration, serum AGE levels may be lower, but
whether this may have influenced skin AGEs is
uncertain. AGEs linked to skin collagen are generally
assumed to be an adequate reflection of overall AGE
status because of the long lifespan of this protein.
Measurement of AGEs in kidney and liver might
reveal aberrant levels of AGEs, because glucose 6-
phosphate and glycogen are known to accumulate in
the liver. Glucose 6-phosphate has a higher potential
of forming AGEs than glucose, so AGEs in kidney and
liver tissue might be increased in GSD Ia patients.
Measurement of AGEs in liver, kidney and urine
might help to understand the role of AGEs in GSD Ia
patients. In support of this, high levels of detoxification
products of the Maillard reaction have been found in a
patient with glycogen accumulation in renal tubular
cells comparable to GSD Ia (Berry et al 2005).
In conclusion, our study confirms that patients with
GSD Ia have a slower progression of atherosclerosis
Fig. 3 The correlation between skin autofluorescence (AF) and
maximum carotid intima-media thickness (IMT) in control
subjects only
Skin AF CLF 370/440 CLF 328/378 Pentosidine CML
CLF 370/440 0.62 (<0.001)
CLF 328/378 0.53 (0.002) 0.96 (<0.001)
Pentosidine 0.26 (NS) 0.61 (<0.001) 0.71 (<0.001)
CML 0.39 (0.031) 0.59 (<0.001) 0.64 (<0.001) 0.53 (0.001)
CEL 0.28 (NS) 0.51 (0.002) 0.52 (0.001) 0.3 (NS) 0.71 (<0.001)
Table 3 Correlations
between skin autofluores-
cence (AF) and AGEs
in skin biopsies in patients
and controls
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GSD Ia is characterized by hypoglycaemia and
previous studies have shown decreased levels of
whole-body excess of reactive oxygen species as mea-
sured by specific oxidative stress markers in the
patients, we hypothesized that this phenomenon could
be explained by decreased formation of AGEs. How-
ever, in the present study, AGE levels, as measured
non-invasively by skin AF and ex vivo in skin biopsies,
did not differ between patients and controls. Hence,
the present results do not further clarify why patients
with GSD Ia avoid early atherosclerosis, as would be
expected by their adverse cardiovascular risk profile,
and suggest that other mechanisms may be involved in
the preserved vascular health of these patients.
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